• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 14

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research

Advanced Shadow Work and Psychedelic Integration: A Jungian Path to Wholeness

Essentials of Psychedelic Therapy & Integration

Pα+ Psychedelic Bulletin #206: Q2’25 Psychedelic Lobbying; Tabernanthalog’s Neuroplasticity Pathway; UK Moves to Ease Schedule I Research Restrictions

GLP-1 Drugs, Psilocybin Mushrooms, and the Case for Sublingual Psilocin

MDMA for Active-Duty Troops: Aaron Wolfgang on DoD’s Unprecedented Study

Opinions: PrEP’s Rollout Offers a Roadmap for Prescription Psychedelics

Exploring Psychedelist with Louis Dorian

Magic Mushrooms Meet Corporate Conspiracy: Steve Hely on Adult Swim’s Common...

Pα+ Psychedelic Bulletin #188: Q4’24 Lobbying Update; Virginia Lawmakers Question Purpose,...

Psychedelic Funding, Public Markets, and M&A in 2024

Neeka Levy and Zach Skiles – Healing Ukraine Trauma

Ketamine on the Edge: Mindbloom’s At-Home Injections Spark Debate; UK Eyes...

Pα+ Psychedelic Bulletin #187: NYT Article Reignites MDMA Rejection Blame Game;...

How Psychedelics Impact the Mind: Mysticism, Mental Health, and the Future...

1...131415...294Page 14 of 294

EDITOR PICKS

From Huxley to Heffter: Mark Geyer Reflects on a Life in...

Advanced Shadow Work and Psychedelic Integration: A Jungian Path to Wholeness

Essentials of Psychedelic Therapy & Integration

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©